Therapeutic Potential of Curcumin in
 ARDS
 and
 COVID
 ‐19

Curcumin is a safe, non-toxic, readily available, and naturally occurring compound, an active constituent of Curcuma longa (turmeric). Curcumin could potentially treat diseases but faces poor physicochemical and pharmacological characteristics. To overcome these limitations, we developed a stable, water-soluble formulation of curcumin (CDC). We have previously shown that direct delivery of CDC to the lung following lipopolysaccharides (LPS) exposure reduces acute lung injury (ALI) and effectively reduces lung injury, inflammation, and mortality in mice following Klebsiella pneumoniae (KP). Recently, we found that administration of CDC led to a significant reduction in angiotensin-converting enzyme 2 (ACE2) and signal transducer and activator of transcription 3 (STAT-3) expression in gene and protein levels following pneumonia, indicating its potential in treating coronavirus disease 2019 (COVID-19). In this review, we consider the clinical features of ALI and acute respiratory distress syndrome (ARDS) and the role of curcumin in modulating the pathogenesis of bacterial/viral-induced ARDS and COVID-19. This article is protected by copyright. All rights reserved.